|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Sunao_Manabe
|
|
gptkbp:collaboratedWith
|
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:divested
|
Ranbaxy Laboratories (to Sun Pharma)
|
|
gptkbp:focus
|
oncology
cardiovascular diseases
rare diseases
|
|
gptkbp:founded
|
2005
|
|
gptkbp:founder
|
gptkb:Sankyo_Co.,_Ltd.
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:hasResearchCenter
|
gptkb:Edogawa_R&D_Center
gptkb:Shinagawa_R&D_Center
|
|
gptkbp:headquartersLocation
|
gptkb:Tokyo,_Japan
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3475350009
|
|
gptkbp:listedOn
|
gptkb:Nikkei_225
|
|
gptkbp:logo
|
Daiichi Sankyo logo.svg
|
|
gptkbp:market
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:memberOf
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:nativeName
|
gptkb:第一三共株式会社
|
|
gptkbp:notable_drug
|
Benicar (olmesartan, US)
Effient (prasugrel)
Enhertu (trastuzumab deruxtecan)
Lixiana (edoxaban)
Olmetec (olmesartan)
|
|
gptkbp:notableAcquisition
|
gptkb:Ranbaxy_Laboratories
|
|
gptkbp:numberOfEmployees
|
16,000+
|
|
gptkbp:parentCompany
|
gptkb:Daiichi_Sankyo_Group
|
|
gptkbp:products
|
gptkb:Enhertu
gptkb:Edoxaban
gptkb:Nexium_(in_Japan)
gptkb:Olmesartan
|
|
gptkbp:rank
|
Top 20 global pharmaceutical companies (by revenue)
|
|
gptkbp:revenue
|
1.2 trillion yen (FY2023)
|
|
gptkbp:romanization
|
gptkb:Daiichi_Sankyō_Kabushiki-gaisha
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4568
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc._(USA)
gptkb:Daiichi_Sankyo_Europe_GmbH
|
|
gptkbp:website
|
https://www.daiichisankyo.com/
|
|
gptkbp:bfsParent
|
gptkb:Japanese_postwar_economic_miracle
gptkb:Azor
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo
|